Lv51
1410 积分 2022-04-30 加入
Cancer burden and control in China: landscape, trends and challenges
1小时前
已完结
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
4天前
已完结
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration
6天前
已完结
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
12天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
1个月前
已完结
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
2个月前
已完结
Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma
2个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2个月前
已完结
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
2个月前
已完结
Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development
3个月前
已完结
皖公网安备34019202002308
